The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Clinical value of PET/CT's SUV max at baseline, early follow-up, and end of treatment reevaluation as a prognostic factor in small cell lung cancer patients with extended disease.
Santiago Ponce Aix
No relevant relationships to disclose
Ray Manneh Kopp
No relevant relationships to disclose
Juan Manuel Sepulveda
No relevant relationships to disclose
Juan A. Núñez
No relevant relationships to disclose
Lara Iglesias
No relevant relationships to disclose
Tomas Pascual
No relevant relationships to disclose
Lucia Parrilla
No relevant relationships to disclose
Sebastian Ruiz Solis
No relevant relationships to disclose